Income Taxes (Details) - USD ($) $ in Thousands |
12 Months Ended | |
|---|---|---|
Dec. 31, 2021 |
Dec. 31, 2020 |
|
| Income Taxes (Details) [Line Items] | ||
| Federal statutory income tax rate | 21.00% | 21.00% |
| Valuation allowance | $ 81,860 | $ 59,099 |
| Change in the valuation allowance | 22,761 | 7,566 |
| Operating loss carryforwards | 517,700 | $ 377,300 |
| Federal research and development credit carryforwards for income tax expense | $ 1,200 | |
| Current carryforwards expiration term | If not used, the current carryforwards will expire beginning in 2034. | |
| State [Member] | ||
| Income Taxes (Details) [Line Items] | ||
| Expiration term | U.S. federal net operating loss carryforwards begin to expire in 2033, and state operating loss carryforwards begin to expire in 2027. | |
| U.S. Federal [Member] | ||
| Income Taxes (Details) [Line Items] | ||
| Expiration term | $248,600 | |
| X | ||||||||||
- Definition Expiration term of the current carryforwards, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Expiration term of each operating loss carryforward included in operating loss carryforward, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. No definition available.
|
| X | ||||||||||
- Definition Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition The amount of the valuation allowance recorded in a business combination against deductible temporary differences for which related tax benefits will be recorded as a reduction of the acquired entity's goodwill and other noncurrent intangible assets. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|